Type6 Therapeutics
- Biotech or pharma, therapeutic R&D
Type6 Therapeutics is transforming precision medicines with a new class of kinase inhibitors that addresses three main challenges within a $60b/y, 700k patients/y drug market: selectivity-based tox, cancer-protective signaling, and resistance mechanisms.
)
)
){kind=logo}
){kind=logo}
){kind=logo}